A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma

Trial Profile

A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CheckMate 143
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Sep 2017 Updated safety results (n=113) of patients with methylated or unmethylated newly diagnosed glioblastoma from cohorts 1c or 1d, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Jul 2017 Status changed from completed to active, no longer recruiting.
    • 05 Jul 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top